#	Aladdin ID	Assay Type	Description	Organism	Compounds	Reference	BAO Format	Source
1.	ALA1054500	F	GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 in whole red blood cells, using parasite LDH activity as an index of growth. Test compounds present at 2uM	Plasmodium falciparum	13,467		organism-based format	GSK Malaria Screening
2.	ALA1054501	F	GSK_TCMDC: Inhibition of Plasmodium falciparum Dd2 in whole red blood cells, using parasite LDH activity as an index of growth. Test compounds present at 2uM	Plasmodium falciparum	13,467		organism-based format	GSK Malaria Screening
3.	ALA1054502	F	GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 LDH activity, using an LDH reporter assay. Test compounds present at 2uM	Plasmodium falciparum	13,467		organism-based format	GSK Malaria Screening
4.	ALA1054503	F	GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 in whole erythrocytes, using parasite LDH activity as an index of growth.	Plasmodium falciparum	13,467		organism-based format	GSK Malaria Screening
5.	ALA1054504	F	GSK_TCMDC: Percent inhibition of human HepG2 cell line. Test compounds present at 10uM.	Homo sapiens	13,467		cell-based format	GSK Malaria Screening
6.	ALA1054505	F	GSK_TCMDC: Inhibition Frequency Index (IFI). The number of non-kinase HTS assays where a compound showed > 50 % inhibition, expressed as a percentage of the number of such assays in which the compound was tested		13,467		assay format	GSK Malaria Screening
7.	ALA1040691	F	NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay	Plasmodium falciparum	5,614		organism-based format	Novartis Malaria Screening
8.	ALA1040692	F	NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay	Plasmodium falciparum	5,614		organism-based format	Novartis Malaria Screening
9.	ALA1040693	T	NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7)	Homo sapiens	5,614		cell-based format	Novartis Malaria Screening
10.	ALA1040694	F	NOVARTIS: Inhibition Frequency Index (IFI) - the number of HTS assays where a compound showed > 50% inhibition/induction, expressed as a percentage of the number of assays in which the compound was tested.		5,614		assay format	Novartis Malaria Screening
11.	ALA1789905	F	NOVARTIS: Antimalarial liver stage activity measured as a greater than 50% reduction in Plasmodium yoelii schizont area in HepG2-A16-CD81 cells at 10uM compound concentration, determined by immuno-fluorescence.	Plasmodium yoelii	4,416		organism-based format	Novartis Malaria Screening
12.	ALA3436042	F	ST_JUDE_LEISH: Cytotoxicity at 2uM final concentration against transgenic Leishmania Mexicana promastigotes LmGLUT1 that are glucose transport deficient and complemented with the human glucose transporter GLUT1. Activity is measured by DNA content using SYBR green in vitro	Leishmania mexicana	13,179		assay format	St Jude Leishmania Screening
13.	ALA3436043	F	ST_JUDE_LEISH: Cytotoxicity at 2uM final concentration against transgenic Leishmania Mexicana promastigotes LmPfHT that are glucose transport deficient and complemented with the Plasmodium falciparum hexose transporter. Activity is measured by by DNA content using SYBR green in vitro	Leishmania mexicana	13,179		assay format	St Jude Leishmania Screening
14.	ALA3436044	F	ST_JUDE_LEISH: Cytotoxicity at 2uM final concentration against transgenic Leishmania Mexicana promastigotes LmGT2 that are glucose transport deficient and complemented with the L. Mexicana glucose transporter 2. Activity is measured by by DNA content using SYBR green in vitro	Leishmania mexicana	13,179		assay format	St Jude Leishmania Screening
15.	ALA3579317	F	Antimicrobial activity against Escherichia coli BW25113 expressing delta-tolC gene incubated for 16 to 18 hrs by macrodilution method	Escherichia coli	16		organism-based format	Scientific Literature
16.	ALA3579318	F	Antimicrobial activity against Escherichia coli BW25113 incubated for 16 to 18 hrs by macrodilution method	Escherichia coli	15		organism-based format	Scientific Literature
17.	ALA3579319	F	Antimicrobial activity against Vibrio cholerae incubated for 16 to 18 hrs by macrodilution method	Vibrio cholerae	4		organism-based format	Scientific Literature
18.	ALA3579320	F	Antimicrobial activity against Salmonella typhimurium incubated for 16 to 18 hrs by macrodilution method	Salmonella enterica subsp. enterica serovar Typhimurium	4		organism-based format	Scientific Literature
19.	ALA3579321	F	Antimicrobial activity against Shigella boydii incubated for 16 to 18 hrs by macrodilution method	Shigella boydii	4		organism-based format	Scientific Literature
20.	ALA3579322	F	Antimicrobial activity against Edwardsiella tarda incubated for 16 to 18 hrs by macrodilution method	Edwardsiella tarda	4		organism-based format	Scientific Literature